Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and building inspection-ready infrastructure without delaying critical submission milestones.

A sponsor developing a novel cell therapy product was preparing for BLA submission while simultaneously establishing commercial manufacturing capabilities. The organization needed to mature QC analytical methods, strengthen data integrity controls, optimize facility design, and implement compliant supply chain processes while transitioning from an R&D-focused culture to a commercial GMP environment. ProPharma partnered with the sponsor through its Cell & Gene Therapy Center of Excellence, embedding a cross-functional team across regulatory, quality, facility, and supply chain functions to drive coordinated execution. This case study explores how ProPharma helped align CMC and validation activities with regulatory expectations, establish ALCOA+-compliant governance and inspection-ready systems, optimize manufacturing and vendor qualification strategies, and implement risk-based oversight frameworks. The result was a more mature, compliant, and scalable organization positioned for confident BLA submission, regulatory inspection readiness, and successful commercial launch.